Sign In
Buy LH
$258.92
+1.22 (+0.473%)
At Close: Jun 03, 2026
Labcorp Announces 2025 First Quarter Results
06:50am, Tuesday, 29'th Apr 2025
Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year: Revenue: $3.35 billion versus $3.18 billion Diluted EPS: $2.52 versus $2.69 Adjusted EPS: $3.8
Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions
07:00am, Wednesday, 23'rd Apr 2025
Labcorp® Plasma Detect™ now available for clinical use to assess risk of recurrence in stage III colon cancer patients FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx now availabl
Labcorp (LH) Earnings Expected to Grow: Should You Buy?
11:07am, Tuesday, 22'nd Apr 2025
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp Q1 Earnings Preview: Diagnostics Arm Likely to Drive Growth
11:20am, Wednesday, 16'th Apr 2025
LH's first-quarter 2025 performance is likely to have benefited from both its Dx and BLS businesses.
Dublin, April 11, 2025 (GLOBE NEWSWIRE) -- The "Genetic Screening Testing for Preventive Health Market - A Global and Regional Analysis: Focus on Test Type, Technology, Application, End User and Count
Labcorp Declares Quarterly Dividend
06:50am, Thursday, 10'th Apr 2025
BURLINGTON, N.C. , April 10, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors h
Is it the Right Time to Retain Labcorp Stock in Your Portfolio?
10:55am, Wednesday, 09'th Apr 2025
LH's growth opportunities in important specialty testing areas are robust. Expanding through strategic acquisitions is an added plus.
Here's Why Labcorp (LH) is a Strong Growth Stock
10:45am, Thursday, 03'rd Apr 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
LH Stock to Gain From Launch of HPV and STI Self-Collection Options
10:46am, Wednesday, 02'nd Apr 2025
Labcorp launches self-collection options for HPV and STI testing in its PSCs.
Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease
07:00am, Wednesday, 02'nd Apr 2025
Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C. , April 2, 2025 /PRNewswire/ -- La
New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen) BURLINGTON, N.C. , Ap
Labcorp to Announce First Quarter Financial Results on April 29, 2025
04:15pm, Monday, 31'st Mar 2025
BURLINGTON, N.C. , March 31, 2025 /PRNewswire/ -- Labcorp Holdings Inc. (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the fir
Why Labcorp (LH) is a Top Growth Stock for the Long-Term
10:46am, Tuesday, 18'th Mar 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Labcorp is Set to Acquire Select Assets of BioReference Health of OPK
11:05am, Friday, 14'th Mar 2025
LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.
Transaction to extend Labcorp's leadership in oncology and expand access to the company's high-quality clinical laboratory services BURLINGTON, N.C. and MIAMI , March 11, 2025 /PRNewswire/ -- Labcorp�
